Stock Report: Zoetis Inc. (ZTS)
Publication Date: September 22, 2024
Company Overview
Zoetis Inc. (ZTS), headquartered in Parsippany, New Jersey, has established itself as a leader in the animal health industry since its founding in 1952. The company specializes in the development and commercialization of veterinary medicines, vaccines, and diagnostic products, serving a wide array of species from livestock to companion animals. With a diverse product lineup, including parasiticides and vaccines, Zoetis caters to veterinarians and animal care providers, solidifying its presence within the Drug Manufacturers – Specialty & Generic sector of the broader Healthcare industry. Analysts have a bullish outlook on Zoetis, recommending it as a “buy,” with a target high price estimated at $248.00 per share, reflecting optimism regarding future growth potential.
Financial Performance
In the recent reporting period, Zoetis achieved a total revenue of approximately $8.92 billion, underscoring its strong market position and operational efficiency. With 453,051,008 shares outstanding, the current stock price stands at $192.64. Analysts suggest significant upside potential, as the mean target price is set at $217.58, alongside a high target of $248.00. The stock shows robust momentum, trading well above its fifty-day moving average of $184.59 and near its 52-week high of $201.92. This performance indicates a favorable investment climate, supported by limited short interest of approximately 0.0113% of the float, suggesting growing confidence among long-term investors.
Market Outlook
Zoetis’ strategic initiatives, such as the collaboration with Blacksmith Medicines, Inc. aimed at developing innovative antibiotics, position it well for future growth in the competitive pharmaceutical landscape. The current stock reflects a promising trend, supported by a mean recommendation score of 1.9 from fifteen analysts, who view the company’s strong revenue and strategic direction as indicators of robust future performance. With a range of projected prices between $172.12 and $248.00, the company represents an appealing opportunity for investors looking for stability and growth in the healthcare sector.
| Metric | Value |
|---|---|
| Market Cap | $87.3b |
| Total Debt | $6.8b |
| Total Cash | $1.6b |
| Shares Outstanding | 453.1m |
| Float Shares | 452.2m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.